autogene cevumeran
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 18, 2023 (NCT05968326)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetOTHER
Personalised cancer vaccine
Targeted to specific tumour neoantigens
- Tumor antigensOTHER
Tumor antigens other
Targeted to specific tumour neoantigens
- Tumor antigensImmunity, active
immunity, active - tumor antigen
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650376 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06534983 | Phase 2 | Jul 31, 2024 | Biontech, Roche |
| NCT05968326 | Phase 2 | Oct 18, 2023 | Biontech, Genentech, Roche |
Showing 2 of 2 trials
Page 1 / 1